Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.

Search

33rd Annual Convention; San Diego, CA; 2007

Event Details


Previous Page

 

Invited Paper Session #498

Contributions of Behavior Analysis to Understanding, Treating, and Preventing Cigarette Smoking

Tuesday, May 29, 2007
12:00 PM–12:50 PM
Douglas B
Area: BPH; Domain: Applied Research
Chair: John M. Roll (Washington State University)
MAXINE STITZER (Behavioral Pharmacology Research Unit)
Dr. Maxine Stitzer is a Professor in the Department of Psychiatry and Behavioral Science at the Johns Hopkins University School of Medicine. Her research portfolio is broadly focused on both pharmacological and behavioral approaches to the treatment of substance abuse and includes research on both illicit drug abuse and tobacco dependence. Dr. Stitzer has published more than 190 scientific papers, and has received several awards acknowledging her research contributions in substance abuse. Her work on tobacco dependence has included studies of withdrawal, craving, and the impact of early abstinence smoking lapse exposure on subsequent relapse behavior. Her research has also contributed to development of nicotine replacement products and to new behavior therapy approaches using contingency management. She has served continuously as a member of the Agency for Health Care Quality and Research Smoking Cessation Guideline panels. She is also a charter member of the Society for Research on Nicotine and Tobacco and has served as president of that organization.
Abstract:

Defining cigarette smoking as operant behavior that is maintained by both pharmacological-based (e.g., nicotine) and conditioned (e.g., taste) reinforcers leads to a number of interesting conclusions and implications. First, it may explain why relapse is such a problem when people try to quit smoking. Second, it suggests that treatment strategies designed to help individuals stop smoking need to prevent exposure to smoking and related cues or at least attenuate the reinforcing efficacy of cigarette smoking if exposure occurs. This could be accomplished through both behavioral and pharmacological means. Finally, it suggests that cigarette smoking prevention may be accomplished by keeping individuals from ever coming in contact with the reinforcing aspects of smoking (e.g., through educational programs or immunotherapy). The address will provide discussion of all of these areas.

 

BACK TO THE TOP

 

Back to Top
ValidatorError
  
Modifed by Eddie Soh
DONATE
{"isActive":false}